Navigation Links
Michael J. Fox Foundation Awards $2 Million for Research on Cognitive and Mood Symptoms of Parkinson's Disease
Date:10/14/2008

odel to better characterize the putative link between dopamine replacement and impulse control problems.

The selection of program awardees was made exclusively by the Foundation under its standard peer-review process. Awards duration ranges from one to three years. As with all MJFF grants, full funding is dependent on fulfillment of predetermined, specific milestones and on researchers' agreement to make the results of their work available to the Parkinson's research community.

About The Michael J. Fox Foundation

Founded in 2000, The Michael J. Fox Foundation for Parkinson's Research is dedicated to ensuring the development of a cure for Parkinson's disease within the decade through an aggressively funded research agenda. The Foundation has funded $128 million in research to date.


'/>"/>
SOURCE Michael J. Fox Foundation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Michael J. Fox Foundation Funds $1.1 Million for Cutting-Edge Approaches to Parkinsons Disease Under Rapid Response Innovation Awards 2008
2. Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee
3. Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinsons Therapeutics
4. Michael J. Fox Foundation Awards $2.4 Million for Validation of Nine Promising Therapeutic Targets for Parkinsons Disease
5. The Foundation for Biomedical Research Announces Winners of the 7th Annual Michael E. DeBakey Journalism Awards
6. Michael J. Fox Foundation Announces $5.6-Million Award for Phase 2 Clinical Trial Studying Neuroprotective Potential of Inosine
7. Michael J. Fox Foundation Commits up to $10 Million for Pre-Clinical Drug Development Under Therapeutics Development Initiative
8. New Michael J. Fox Foundation Initiative Will Drive Development of Web-Based Tools to Increase Patient Participation in Parkinsons Clinical Trials
9. Michael J. Fox Foundation Commits Up to $3 Million for Clinical Trials That Can Improve Treatment of Parkinsons Disease
10. Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development
11. Alzheimers Foundation of America Survey: Americans With Memory Concerns Fall Short of Talking to Doctors

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...wire-FirstCall/--NuVasive,Inc.(Nasdaq: NUVA ),amed...imallydisruptivesurgicaltreatmentsforthespine,anno...vember30,2009,at5:30p.m.ET/2:30p.m.PT.Theconferenc...ntfortheCompany,sproductsandwillincludecommentsfro...n.Thedial-innumbersare1-877-407-4018fordomesticcal...
(Date:11/25/2009)...dJOHANNESBURG,November25/PRNewswire/--,iThembaPhar...cedtoday,thattheyhavesignedacollaborativeagreement...is,sworldclasscomputationalchemistryandleaddiscove...iontoprovidemedicinaland,syntheticchemistrysupport...entnetwork.iThembaPharmaceuticalsandPyxisDiscovery...
(Date:11/24/2009)...wswire/-- ,, WHAT:RomHoubens,aBelgianmanthought...wasactuallyfullyconsciousandawakeduringthattimeand...oxEyeMaxwasfeaturedinthesegmenttoillustratehowpeop...communication. ,, WHEN:GoodMorningAmerica-- Tue...ch.com ,, WHO:RomHoubenswasanengineeringstu...
Breaking Medicine Technology:NuVasive Announces Conference Call and Webcast Regarding Reimbursement 2NuVasive Announces Conference Call and Webcast Regarding Reimbursement 3iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering 2DynaVox EyeMax Featured in Good Morning America Segment About Man Thought To Be in Coma for 23 Years 2FDA Approves NovoLog 28R 29 Labeling Update 51814 1FDA Approves NovoLog 28R 29 Labeling Update 51814 2FDA Approves NovoLog 28R 29 Labeling Update 51814 3FDA Approves NovoLog 28R 29 Labeling Update 51814 4U S Students Academic Interests Tend to Wane in Middle School 51812 1U S Students Academic Interests Tend to Wane in Middle School 51812 2Michael Steele Chairman of the Republican National Committee Will Hold a Press Conference on Health Care the Republican Alternative at 9 am on Mon 51810 1
...at data,presented recently at the 17th Annual Meet...iology demonstrate that the Genous Bio-engineered ...eluting stents., Presented by Federico Piscione, ...fessor with the Federico II University of Naples,s...dicine and Cardiovascular,Sciences, the data were ...
...ion Application currently u...erapeutics, Inc. (CTI),(Nasdaq: CTIC ; MTA) today...domized phase III trial comparing OPAXIO(TM) (pacl...orelbine for the treatment of PS 2,(performance st...ll cell,lung cancer (NSCLC) in the Journal of Thor...
Other Medicine Technology:Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeich's Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents 2Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeich's Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents 3Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 2Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 3Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 4Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 5
(Date:11/27/2009)...UILLY-SUR-SEINE,France,Nov.27/PRNewswire/--TeamGar...teamdedicatedtoethicalsportinganddevelopingthenext...illbecomeTeamGarmin-TransitionswiththeadditionofTr...Opticalistheworld,sleadingmanufacturerofadaptiveey...yinthewidestselectionofspectaclelensessuchasTransi...
(Date:11/27/2009)... XenaCare Holdings has announced th...is Foundation, one of the largest nonprofit organi... health education. , Delr... Holdings, Inc. (OTCBB: XCHO), a company specializ...nsumer healthcare products, has announced today th...
(Date:11/27/2009)...tes to bring unprecedented medical, economic burde...HealthDay News) -- The number of people with diabe...r the next 25 years, a new study predicts. , Th...lion people with the disease, up from 23.7 million...ng people with diabetes will triple, the study als...
(Date:11/27/2009)... Voyant Health™ announced tod...as licensed its TraumaCad Enterprise orthopedic te...w solution. , (PRWEB) Nov...oday that Spectrum Health (Grand Rapids, Michigan)...templating solution and its TraumaCad Extend workf...
(Date:11/27/2009)... Specialist manufacturers who use m...re saving millions of dollars by bringing in techn... Increasing numbers of pro-active medical manufact...the concept stage of their projects, ensuring that...gn processes or potentially outdated technology. ...
Breaking Medicine News(10 mins):Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 4Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4
...LLE, Pa., Dec. 21 RESPIRONICS, INC.,(Nasdaq: RES...ve merger,agreement pursuant to which Royal Philip... commence a tender offer to acquire all of the out... a,premium of approximately 31% over Respironics, ...
... study finds that most general surgeons do not dis...breast cancer treatment. The analysis shows that o...or breast conserving surgery have such discussions...nstruction has increased treatment choices for wom...
...Calif., Dec. 20 ISTA Pharmaceuticals,Inc. (Nasdaq...ed a New Drug,Application (NDA) to the U.S. Food a...ce-daily). The Company is seeking approval for Xib...opical non-steroidal anti-inflammatory compound fo...
...om Community Will Fund 20 Percent of Cost for New ...undation announced that it has reached its $50 mil...mportant philanthropic effort Sharp has ever,under...com/cgi-bin/prnh/20071220/DC10448 ), "It,s only ...
...ON, Dec. 20 Today URAC called for,comments on maj...alth Web,Site, HIPAA Privacy (Business Associate a...sociate and Covered Entity) accreditation programs...ne for public comment is Feb. 10, 2008., (LOGO: ...
...N, Va., Dec. 20 MCG Capital,Corporation (Nasdaq: ...ferred,equity investment to support the acquisitio...ld & Lamb is a medical-financial services company ...tion industry,since 2001. Having completed in exce...
Other Medicine News:Health News:Royal Philips Electronics to Acquire Respironics for USD $66.00 Per Share 2Health News:Royal Philips Electronics to Acquire Respironics for USD $66.00 Per Share 3Health News:Royal Philips Electronics to Acquire Respironics for USD $66.00 Per Share 4Health News:Royal Philips Electronics to Acquire Respironics for USD $66.00 Per Share 5Health News:Reconstruction surgery rarely discussed with breast cancer patients 2Health News:ISTA Pharmaceuticals Submits New Drug Application for Xibrom(TM) QD (once-daily) 2Health News:Sharp HealthCare Foundation Reaches $50 Million Goal 2Health News:Sharp HealthCare Foundation Reaches $50 Million Goal 3Health News:URAC Calls for Comments on Changes to Standards for Health Web Site, HIPAA Privacy and Security Accreditation Programs 2Health News:MCG Capital Invests in Gould & Lamb 2
...ested Timeter® Classic Flowmeters demonstrates...oviders and patients alike. You can see it in the ... can see it in the performance, year after year. E...d and engineered to the highest standards of perfo...
Soft-Touch Timeter® 15 LPM Dual Oxygen Flowmeter w/Y Bar & 2 Power Take Off
Soft-Touch Timeter® 15 LPM Dual Oxygen Flowmeter w/T Bar
Soft-Touch Timeter® 8 LPM Flowmeter
Medicine Products: